Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

346 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Novel small molecule inhibitors of the OLIG2 transcription factor: promising new therapeutics for glioblastoma.
Alton G, Kesari S. Alton G, et al. Among authors: kesari s. Future Oncol. 2016;12(8):1001-4. doi: 10.2217/fon-2015-0078. Epub 2016 Feb 12. Future Oncol. 2016. PMID: 26867754 No abstract available.
The central nervous system-restricted transcription factor Olig2 opposes p53 responses to genotoxic damage in neural progenitors and malignant glioma.
Mehta S, Huillard E, Kesari S, Maire CL, Golebiowski D, Harrington EP, Alberta JA, Kane MF, Theisen M, Ligon KL, Rowitch DH, Stiles CD. Mehta S, et al. Among authors: kesari s. Cancer Cell. 2011 Mar 8;19(3):359-71. doi: 10.1016/j.ccr.2011.01.035. Cancer Cell. 2011. PMID: 21397859 Free PMC article.
DNA damage response and repair: insights into strategies for radiation sensitization of gliomas.
Kesari S, Advani SJ, Lawson JD, Kahle KT, Ng K, Carter B, Chen CC. Kesari S, et al. Future Oncol. 2011 Nov;7(11):1335-46. doi: 10.2217/fon.11.111. Future Oncol. 2011. PMID: 22044206 Free PMC article. Review.
Multiple spatially related pharmacophores define small molecule inhibitors of OLIG2 in glioblastoma.
Tsigelny IF, Mukthavaram R, Kouznetsova VL, Chao Y, Babic I, Nurmemmedov E, Pastorino S, Jiang P, Calligaris D, Agar N, Scadeng M, Pingle SC, Wrasidlo W, Makale MT, Kesari S. Tsigelny IF, et al. Among authors: kesari s. Oncotarget. 2017 Apr 4;8(14):22370-22384. doi: 10.18632/oncotarget.5633. Oncotarget. 2017. PMID: 26517684 Free PMC article.
Treatment for Patients With Newly Diagnosed Glioblastoma--Reply.
Stupp R, Toms SA, Kesari S. Stupp R, et al. Among authors: kesari s. JAMA. 2016 Jun 7;315(21):2348-9. doi: 10.1001/jama.2016.1847. JAMA. 2016. PMID: 27272591 No abstract available.
Molecular mechanisms of OLIG2 transcription factor in brain cancer.
Tsigelny IF, Kouznetsova VL, Lian N, Kesari S. Tsigelny IF, et al. Among authors: kesari s. Oncotarget. 2016 Aug 16;7(33):53074-53101. doi: 10.18632/oncotarget.10628. Oncotarget. 2016. PMID: 27447975 Free PMC article.
Anti-cancer effects of nitrogen-containing bisphosphonates on human cancer cells.
Jiang P, Zhang P, Mukthavaram R, Nomura N, Pingle SC, Teng D, Chien S, Guo F, Kesari S. Jiang P, et al. Among authors: kesari s. Oncotarget. 2016 Sep 6;7(36):57932-57942. doi: 10.18632/oncotarget.10773. Oncotarget. 2016. PMID: 27462771 Free PMC article.
Brainstem Glioma in Adults.
Hu J, Western S, Kesari S. Hu J, et al. Among authors: kesari s. Front Oncol. 2016 Aug 9;6:180. doi: 10.3389/fonc.2016.00180. eCollection 2016. Front Oncol. 2016. PMID: 27556016 Free PMC article. Review.
Efficacy and Safety of Treating Glioblastoma With Tumor-Treating Fields Therapy.
Saria MG, Kesari S. Saria MG, et al. Among authors: kesari s. Clin J Oncol Nurs. 2016 Oct 1;20(5 Suppl):S9-S13. doi: 10.1188/16.CJON.S1.9-13. Clin J Oncol Nurs. 2016. PMID: 27668388 Review.
RSK2 activity mediates glioblastoma invasiveness and is a potential target for new therapeutics.
Sulzmaier FJ, Young-Robbins S, Jiang P, Geerts D, Prechtl AM, Matter ML, Kesari S, Ramos JW. Sulzmaier FJ, et al. Among authors: kesari s. Oncotarget. 2016 Nov 29;7(48):79869-79884. doi: 10.18632/oncotarget.13084. Oncotarget. 2016. PMID: 27829215 Free PMC article.
346 results
Jump to page
Feedback